Substituted phenols and their use for the treatment of disorders caused by cell proliferation

Abstract

Substituted phenols of the formula I ##STR1## processes for their preparation and compositions containing substituted phenols of the formulae I and II ##STR2## for the treatment of disorders caused by cell proliferation, such as psoriasis, tumor disorders and immunological disorders, are described.

Description

The invention relates to substituted phenols of the formula I, processes for their preparation and compositions containing substituted phenols of the formulae I and II for the treatment of disorders caused by cell proliferation, such as psoriasis, tumor disorders and immunological disorders.

It is already known that substituted phenols are suitable for the treatment of tumor disorders (EP 0322738 and EP 0238868), whereby it has been found that certain substituted phenols inhibit tyrosine kinase activity of the EGF (epidermal growth factor) receptor and thus block the growth of tumor cells. It is further known that tyrosine kinase play a crucial part in the T- and B-cell activation of the immune system and in the activation of mast cells and basophilic leucocytes and thus the secretion of histamine.

It is an object of the invention to obtain better compounds for the treatment of tumor disorders and immunological disorders.

It has surprisingly been found that substituted phenols of the formulae I and II have an activity against proliferating tumor cells, in which they strongly inhibit the EGF receptor tyrosine kinase.

The invention relates to compounds of the formula I ##STR3## where R.sub.2 is methyl, ethyl, hexyl, isopropyl, N-dimethylamino, N-morpholino, benzyl, N-piperidine, N-homopiperidine, 4-benzoic acid, 3-halophenyl, 4-halophenyl, N-piperazine, N-4-methylpiperazine, or an amino acid residue with the exception of glycine and methionine, preferably ##STR4## or its esters.

The invention also relates to a process for the preparation of the compounds of the formula I, which comprises dissolving or suspending 2,5-dihydroxybenzaldehyde in a suitable solvent, preferably toluene, and heating with the equivalent amount of the corresponding amine under reflux in a water-separating apparatus until the elimination of water is complete, or dissolving 2,5-dihydroxy-benzaldehyde with the equimolar amount of the corresponding amine in dried methanol and heating to about 60.degree. C., preferably for about 24 h. After cooling, the solvent is stripped off, for example in a rotary evaporator under reduced pressure. The residue is taken up in toluene/ethanol and recrystallized.

The invention additionally relates to pharmaceuticals which contain a compound of the formula I or a compound of the formula ##STR5## where R.sub.1 and R.sub.2 are H or together are a fused aromatic system, preferably a carbocyclic system preferably having up to 8 carbon atoms, which can be substituted, preferably by up to 2 hydroxy groups

R.sub.3 is H or OH R.sub.4 and R.sub.5 independently of one another are H, C.sub.1 -C.sub.4 -alkyl, preferably methyl, sulfonic acid, aryl, preferably phenyl, hydroxyl, CHO or halogen, where at least one of the radicals R.sub.1 -R.sub.5 is not H or a Schiff's base of the formula--CH.dbd.N--R.sub.6, and R.sub.6 is alkyl, N-dimethylamino, cyclohexyl, N-morpholino, benzyl, N-piperidine, N-homopiperidine, aryl, haloaryl, carboxyaryl or hydroxyaryl where aryl is preferably phenyl, or is N-piperazine, N-4-methylpiperazine or an amino acid radical, preferably ##STR6## or its esters.

For R.sub.3 =OH the invention also relates to the corresponding quinones.

These pharmaceuticals contain substituted phenols according to the invention. The pharmaceuticals according to the invention are prepared by bringing at least one substituted phenol into a suitable administration form, if appropriate using further auxiliaries and/or excipients. The auxiliaries and excipients are derived from the group comprising excipients, preservatives and other customary auxiliaries.

For the control of tumor disorders and immune diseases, the compounds according to the invention can be administered in various ways, for example, they can be administered intravenously, intramuscularly, intraperitoneally, subcutaneously, as a continuous drip infusion, rectally or orally. In the case of acute disease conditions, administration as a continuous drip infusion is to be preferred. For continuous medication, for example, oral administration is indicated.

For example, for oral administration forms auxiliaries such as starches, e.g. potato, corn or wheat starch, cellulose or its derivatives, in particular microcrystalline cellulose, silica, various sugars such as lactose, magnesium carbonate and/or calcium phosphates can be used. It is furthermore advantageous to add auxiliaries which improve the tolerability of the medicaments to the oral administration forms, such as for example, mucilaginous agents and resins. To improve tolerability, the medicaments can also be administered in the form of enteric-coated capsules. Moreover, it may be advantageous to add a sustained-release agent to the administration form, or to a component of the combination preparation, if appropriate in the form of permeable membranes, such as for example, those based on cellulose or polystyrene, or ion exchangers.

The dose of the pharmaceuticals according to the invention to be used is dependent on various factors such as the administration form of the medicament and the condition, weight and nature of the disorder of the patient. A daily dose of about 5000 mg of a substituted phenol should only be exceeded for a short time, however. About 10 to 2500 mg of substituted phenol are preferred as a daily dose for a human of body weight about 70 kg. The daily dose of the substituted phenols can be administered in the form of an individual administration or in several smaller doses. Administration in 3 to 8 doses per day is preferred. In some cases, a continuous supply of the substituted phenols may be indicated, e.g. in the form of a continuous drip infusion.

These pharmaceuticals are suitable for the control of diseases which are caused by uncontrolled cell proliferation (cell activation). They are effective for the inhibition of cell proliferation, in particular of immune cell and tumor cell proliferation, and the inhibition of the activation of mast cells and basophilic leucocytes, i.e. for the treatment of psoriasis, tumor disorders and immune diseases.

EXAMPLES

Example 1-14

General working procedure for the preparation of N-substituted 2,5-dihydroxybenzaldimines (method A)

250 mg (1.8 mmol) of 2,5-dihydroxybenzaldehyde are dissolved or suspended in toluene using the equimolar amount of the corresponding amine and the mixture is heated under reflux for 12 h in a water-separating apparatus. After cooling, the solvent is stripped off under reduced pressure in a rotary evaporator. The residue is taken up in toluene/ethanol and recrystallized.

General working procedure for the preparation of N-substituted 2,5-dihydroxybenzaldimines (method B )

250 mg (1.8 mmol) of 2,5-dihydroxybenzaldehyde are dissolved in dried methanol with the equimolar amount of the corresponding amine and the solution is heated at 60.degree. C. for 24 h. After cooling, the solvent is stripped off under reduced pressure in a rotary evaporator. The residue is taken up in toluene/ethanol and recrystallized.

______________________________________ Yield M.p. (% of Amine Method (.degree.C.) theory)______________________________________1. 4-[N-(2',5'-Di- 4-Aminobenzoic A 205 78 hydroxybenzyl- acid idene)amino]- benzoic acid2. 2,5-Dihydroxy-N- Methylamine B 122 65 methylbenzal- dimine3. N-Benzyl-2,5-di- Benzylamine A 118 40 hydroxybenzal- dimine4. 2,5-Dihydroxy-N, N,N-dimethyl- B 111 25 N-dimethyl- hydrazine benzaldehyde hydrazone5. (S)-.alpha.-N-(2,5-Di- Histidine B 110 15 hydroxybenzyl- methyl ester idene)histidine methyl ester6. N-Hexyl-2,5-di- Hexylamine A 95 75 hydroxybenzal- dimine7. N-Ethyl-2,5- Ethylamine B 145 75 hydroxybenzal- dimine8. 2,5-Dihydroxy-N- Isopropylamine B 135 70 isopropylbenzal- dimine9. N-(4'-Chloro- 1-Amino-4- A 170 70 phenyl)-2,5-di- chlorobenzene hydroxybenzal- dimine10. 2,5-Dihydroxy-N- 1-Aminopiperi- B 177 50 piperidinobenzal- dine dimine11. 2,5-Dihydroxy-N- 4-Amino- B 172 60 morpholino- morpholine benzaldimine12. 2,5-Dihydroxy-N- 1-Amino-4- B 250 65 (4'-methylpiper- methyl- azino)benzal- piperazine dimine13. (S)-N-(2',5'-Dihy- Tyrosine B 131 20 droxybenzyl- idene)tyrosine methyl ester14. (S)-N-(2',5'-Dihy- Phenylalanine B 107 20 droxybenzyl- idene)phenyl- alanine methyl ester______________________________________

Example 15

Test for EGF receptor tyrosine kinase inhibition

The starting material for tyrosine kinase activity was the human tumor cell line A 431 (ATCC CRL 1555), which was cultured in RPMI 1640 medium+10% FCS. This cell line expresses a large number of EGF receptors which have tyrosine kinase activity on the cell surface. The cells were cultured almost to confluence, washed with PBS (phosphate buffered saline, pH 7.2), scraped off the culture flask and incubated at 4.degree. C. for 1 h, subjected to 20 strokes in a Potter and centrifuged at 1000 g for 30'. The supernatant was centrifuged at 20000 g for a further 20 min and the pellet was taken up in 100 .mu.l per 1.times.10.sup.6 cells as the membrane preparation.

The tyrosine kinase activity of the EGF receptor (EGFRTK) was measured using poly(Glu, Ala, Tyr), 6:3:1, as the substrate. The cell membranes were pretreated with 1000 nM EGF at RT for 15'and then added to the batch which contains the inhibitor, substrate (3 mg/ml), Mg.sup.2+ /Mn.sup.2+ (8 mM/1.6 mM), 0.16% Triton X-100 and sodium ortho-vanadate (20 .mu.M) in 100 mM HEPES (N-2-hydroxyethyl-piperazine-N'-2-ethanesulfonic acid), pH 7.5, preincubated and the reaction initiated by addition of gamma-.sup.32 P ATP (32 .mu.M). After 15'at 30.degree. C., the substrate was precipitated with 10% TCA (trichloroacetic acid), filtered on a millititer filtration plate (Millipore Corporation, Massachusetts, USA), washed and dried. The incorporation of .sup.32 P was determined by means of a liquid scintillation counter.

Results:

The substituted phenols were tested at a maximum concentration of 51 .mu.g/ml and diluted stepwise 1:10. IC.sub.50 indicates the concentration at which 50% of the starting enzyme activity was inhibited (Table 1).

Example 16

Test for 3',5'-cAMP-dependent protein kinase inhibition

The catalytic subunit of the cAMP-dependent protein kinase (PKA) (Sigma) was reconstituted as described by Sigma (Sigma Chemical Co., St. Louis, Mo. USA). The enzyme activity was measured using Kemptide (Sigma) (Leu-Arg-Arg-Ala-Ser-Leu-Gly) as a substrate. The inhibitor was preincubated with enzyme, substrate (190 .mu.M), Mg.sup.2+ (5 mM), 0.25 mg/ml of BSA and 3.75 mM mercaptoethanol in 50 mM MOPS (4-morpholinopropanesulfonic acid), pH 6.9. The reaction was initiated by addition of gamma-.sup.32 P ATP (40 .mu.M) After 15'at 30.degree. C., an aliquot part was added to p81 ion exchanger (2.times.2 cm; Whatman Paper Ltd., Great Britain), immersed in 75 mM H.sub.3 PO.sub.4, washed, dried, and the incorporation of .sup.32 P was determined by means of a liquid scintillation counter.

Results:

The substituted phenols were tested at a maximum concentration of 40 .mu.g/ml, and the % inhibition indicates the inhibition of the starting enzyme activity (Table 1).

TABLE 1______________________________________Inhibition of the enzymatic activity of protein kinasesby substituted phenols. PKA EGFRTK % inhib.Substance IC.sub.50, .mu.g/ml at 40 .mu.g/ml______________________________________Hydroquinone 0.1 n.t.Benzoquinone 0.05 45Menadiol 26.2 0Naphthoquinone 0.2 462-Methylhydroquinone 1.1 46Potassium hydroquinone-2-sulfonate 1.84 12-Phenylhydroquinone 1.03 252-tert-Butylhydroquinone 0.95 22Pyrocatechol 1.6 0Gentisaldehyde 20-30 n.t.1,2,4-Trihydroxybenzene 24.0 01,4-Naphthodiol 1.5 761,4-Anthraquinone 0.58 n.t.2,5-Dihydroxy-N-(4'-hydroxyphenyl)- 12.63 n.t.benzaldimine2,5-Dihydroxy-N-phenylbenzaldimine 19.04 n.t.3-[-(2',5'-Dihydroxybenzylidene)- 20.05 0amino]benzoic acid4-[N-(2',5'-Dihydroxybenzylidene)- 17.37 0amino]benzoic acid (Ex. 1)5-[N-(2',5'-Dihydroxybenzylidene)- 7.45 0amino]-2-hydroxybenzoic acidN-Hexyl-2,5-dihydroxybenzaldimine 21.16 0(Ex. 6)2,5-Dihydroxy-N-methylbenzaldimine 1.98 0(Ex. 2)2,5-Dihydroxy-N-isopropylbenzal- 12.25 0dimine (Ex. 7)Quinhydrone 0.126 0N-Isopropyl-2,5-dihydroxybenzal- 8.3 0dimine (Ex. 8)N-Benzyl-2,5-dihydroxybenzaldimine 1.7 0(Ex. 3)2,3-Dimethylhydroquinone 0.641 712-Chlorohydroquinone 1.89 02-Chlorobenzoquinone 1.38 292,5-Dihydroxy-N-piperidinobenzal- 10.51 0dimine (Ex. 10)2,5-Dihydroxy-N-morpholinobenzal- 2.77 0dimine (Ex. 11)2,5-Dihydroxy-N-(4'-methylpiper- 0.56 0azino)benzaldimine (Ex. 12)N-Homopiperidino-2,5-dihydroxy- 4.08 0benzaldimine4-[N-(2',5'-Dihydroxybenzyl)- 4.61 61amino]benzoic acidN-Cyclohexyl-2,5-dihydroxy- 9.8 61benzaldimine2,5-Dihydroxy-N,N-dimethylbenzal- 1.38 63dehyde hydrazone (Ex. 4)(S)-alpha-N-(2',5'-Dihydroxy- 12.64 0benzylidene)histidine methyl ester(Ex. 5)______________________________________

Example 17

Test for inhibition of EGF- or bFGF-stimulated proliferation of tumor cells

2.times.10.sup.3 hela cells per well were inoculated into a 96-well microtiter plate (in RPMI+1% FCS ). After 24 h, the medium was changed to RPMI+0.5% FCS and various concentrations of the test substance.+-.EGF (0.1 nM)/bFGF (1 ng/ml) were added. Each group consisted of 4 wells; the control was only incubated.+-.growth factor. After 65 h, 50 .mu.of MTT (2.5 mg/ml in PBS) were added and the supernatant was removed after 7 h. The colored substance formed by the living cells was dissolved by addition of 100 .mu.l of DMSO/well. The absorption was measured at 492 nm for each well with the aid of a 340 CC Multiscan photometer (Flow).

Results:

The mean value is formed from the 4 wells of a group and the absorption difference between the controls.+-. growth factor (A) and between the groups with test substance.+-. growth factor (B) is determined. The % inhibition of the stimulation of growth factor is calculated by ##EQU1## and is listed in Table 2.

TABLE 2______________________________________ EGF stimulation % inhibition at .mu.g/mlSubstance 0.2 1 5 25______________________________________Hydroquinone 29 43Benzoquinone 36 55Menadiol n.t.Naphthoquinone 11 tox2-Methylhydroquinone 21 66Potassium hydroquinone-2-sulfonate 6 142-Phenylhydroquinone 11 662-tert-Butylhydroquinone 21 52Pyrocatechol 16 35Gentisaldehyde 0 161,2,4-Trihydroxybenzene 5 tox1,4-Naphthodiol 29 tox1,4-Anthraquinone 33 tox2,5-Dihydroxybenzylidene-4-hydroxyaniline 39 tox2,5-Dihydroxybenzylideneaniline 24 tox(2,5-Dihydroxybenzylidene)-3-aminobenzoic 44 toxacid(2,5-Dihydroxybenzylidene)-4-aminobenzoic 48 toxacid (Ex. 1)(2,5-Dihydroxybenzylidene)-5-amino-2- 51 toxhydroxybenzoic acidN-Hexyl-2,5-dihydroxybenzaldimine (Ex. 6) 18 toxN-Methyl-2,5-dihydroxybenzaldimine 21 tox(Ex. 2)N-Ethyl-2,5-dihydroxybenzaldimine (Ex. 7) 28 toxQuinhydrone 12 64N-Isopropyl-2,5-dihydroxybenzaldimine 28 tox(Ex. 8)N-Benzyl-2,5-dihydroxybenzaldimine (Ex. 3) 28 tox2,3-Dimethylhydroquinone 17 tox2-Chlorohydroquinone 46 tox2-Chlorobenzoquinone 29 tox(2,5-Dihydroxybenzylidene)-1-amino- n.t.piperidine (Ex. 10)(2,5-Dihydroxybenzylidene)-4-amino- 17 toxmorpholine (Ex. 11)(2,5-Dihydroxybenzylidene)-1-amino- 21 tox4-methylpiperazine (Ex. 12)(2,5-Dihydroxybenzylidene)-1-amino- toxhomopiperidineN-2,5-Dihydroxybenzyl-4-aminobenzoic 36 toxacidN-Cyclohexyl-2,5-dihydroxybenzaldimine 39 64N-(2,5-Dihydroxybenzylidene)-N',N'-di- 46 toxmethylhydrazine (Ex. 4)(S)-alpha-N-(2',5'-Dihydroxybenzylidene)- 10 44histidine methyl ester (Ex. 5)______________________________________ n.t. = not tested tox = toxic

Claims

1. A compound of the formula I ##STR7## where R.sub.2 is methyl, ethyl, hexyl, isopropyl, N-dimethylamino, N-morpholino, benzyl, N-piperidine, N-homopiperidine, 4-benzoic acid, 3-halophenyl, 4-halophenyl, N-piperazine, N-4-methylpiperazine, or an amino acid residue with the exception of glycine and methionine, or its esters.

2. A compound according to claim 1, wherein the amino acid residue is ##STR8##

3. A pharmaceutical, which contains a compound of the formula I as claimed in claim 1 or of the formula II ##STR9## where R.sub.1 and R.sub.2 are H or together are a carbocyclic system having up to 8 carbon atoms substituted by up to two hydroxyl groups,

R.sub.3 is H or OH, with the proviso that when R.sub.1 and R.sub.2 are together a carbocyclic system having 6 carbons, R.sub.3 is OH,

R.sub.4 and R.sub.5 independently of one another are H, C.sub.1 -C.sub.4 -alkyl, sulfonic acid, aryl, hydroxyl, CHO or halogen or a Schiff's base of the formula --CH.dbd.N--R.sub.6, where at least one of the radicals R.sub.1 -R.sub.5 is not H,

and R.sub.6 is alkyl, N-dimethylamino, cyclohexyl, N-morpholino, benzyl, N-piperidine, N-homo-piperidine, aryl, haloaryl, carboxyaryl or hydroxyaryl, or is N-piperazine, N-4-methyl-piperazine or an amino acid radical, or its esters and an auxiliary and/or excipient.

4. A pharmaceutical according to claim 3, wherein R.sub.4 and R.sub.5 are methyl.

5. A pharmaceutical according to claim 3, wherein R.sub.4 and R.sub.5 are phenyl.

6. A pharmaceutical according to claim 3, wherein the aryl in R.sub.6 is phenyl.

7. A pharmaceutical according to claim 3, wherein R.sub.1 and R.sub.2 together are a carbocyclic system having up to 8 carbon atoms substituted by up to 2 hydroxyl groups.

8. A method for the treatment of diseases which are caused by uncontrolled proliferation of cells which comprises administering to a host in need thereof an effective amount of a compound of the formula I as claimed in claim 1.

9. A method as claimed in claim 8, where psoriasis is treated.

10. A method for the treatment of diseases which are caused by the uncontrolled proliferation of cells which comprises administering to a host in need thereof an effective amount of a compound of the formula II: ##STR10## wherein R.sub.1 and R.sub.2 are H or together are a carbocyclic system having up to 8 carbon atoms substituted by up to two hydroxyl groups,

R.sub.3 is H or OH, with the proviso that when R.sub.1 and R.sub.2 are together a carbocyclic system having 6 carbons, R.sub.3 is OH,

R.sub.4 and R.sub.5 independently of one another are H, C.sub.1 -C.sub.4 -alkyl, sulfonic acid, aryl, hydroxyl, CHO or halogen or a Schiff's base of the formula --CH.dbd.N--R.sub.6, where at least one of the radicals R.sub.1 -R.sub.5 is not H,

and R.sub.6 is alkyl, N-dimethylamino, cyclohexyl, N-morpholino, benzyl, N-piperidine, N-homopiperidine, aryl, haloaryl, carboxyaryl or hydroxyaryl, or is N-piperazine, N-4-methyl-piperazine or an amino acid radical, or its ester and an auxiliary and/or excipient.

11. A method as claimed in claim 10, where psoriasis is treated.